Newron Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference in New York

MILAN–(BUSINESS WIRE)– Newron
Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central nervous system (CNS) and pain,
today announced that Stefan Weber, CEO, will present at the Jefferies
2016 Healthcare Conference in New York, NY on Tuesday, June 7, 2016 at
3:00 p.m. ET.

The Jefferies
Healthcare Conference features an extensive range of public and
private healthcare companies across the biopharmaceuticals, life
sciences, healthcare services, healthcare IT and medical technology
sectors. The conference addresses investment opportunities and discuss
the mechanisms driving healthcare in the U.S. and internationally.

About Newron Pharmaceuticals
Newron (SIX: NWRN) is a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central nervous system (CNS) and pain.
The Company is headquartered in Bresso near Milan, Italy. Xadago®
(Safinamide) has received marketing authorization for the treatment of
Parkinson’s disease in the European Union and Switzerland and is
commercialized by Newron’s Partner Zambon. US WorldMeds holds the
commercialization rights in the US. Meiji Seika has the rights to
develop and commercialize the compound in Japan and other key Asian
territories. In addition to Xadago® for Parkinson’s disease, Newron has
a strong pipeline of promising treatments for rare disease patients at
various stages of clinical development, including sarizotan for patients
with Rett syndrome and ralfinamide for patients with specific rare pain
indications. Newron is also developing NW-3509 as the potential first
add-on therapy for the treatment of patients with positive symptoms of
schizophrenia.
For more information, please visit: www.newron.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160525005184/en/